Dr. Wysham goes over the details of how the new SGLT2 compounds work, and talks about the benefits and disadvantages of these potential new agents, including previous concerns around bladder cancer with dapagliflozin, giving us an update on the latest news.
More videos with Dr. Wysham:
Dr. Carol Wysham is Adjunct Research Professor within the Department of Pharmacotherapy at Washington State University, Assistant Clinical Professor of Medicine at the University of Washington School of Medicine and is Section Head of the Department of Endocrinology at Rockwood Clinic in Spokane, Washington. Her current areas of research interest include reduction of CVD risk in type 2 diabetes and improving delivery of care for diabetes. She has been involved with numerous trials for the National Institute of Health including the ACCORD Trial and the AIM-High Trial.